Casdin Capital, LLC Jounce Therapeutics, Inc. Transaction History

Casdin Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 13, 2019	SELL	$2.69 - $6.71 $1.01 Million - $2.52 Million	-375,000 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$7.27 - $21.88 $1.89 Million - $5.69 Million	-260,000 Reduced 40.94%	375,000 $2.87 Million
Q1 2018 May 15, 2018	BUY	$13.4 - $28.4 $2.14 Million - $4.54 Million	160,000 Added 33.68%	635,000 $14.2 Million
Q4 2017 Feb 14, 2018	BUY	$12.52 - $17.82 $941,191 - $1.34 Million	75,175 Added 18.8%	475,000 $6.06 Million
Q3 2017 Nov 14, 2017	BUY	$11.17 - $16.99 $4.47 Million - $6.79 Million	399,825	399,825 $6.23 Million

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Casdin Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Casdin Capital, LLC with notifications on news.